Lecanemab, sold under the brand name Leqembi, is a monoclonal antibody medication used for the treatment of Alzheimer's disease. Lecanemab is an amyloid...
30 KB (2,672 words) - 07:01, 6 December 2024
Anti-amyloid drugs (section Lecanemab)
reasons. Lecanemab, sold under the brand name Leqembi, is a monoclonal antibody medication used for the treatment of Alzheimer's disease. Lecanemab is an...
9 KB (2,453 words) - 23:13, 13 December 2024
Monoclonal antibody therapy (section Lecanemab)
for Alzheimer's disease, Aducanemab and Lecanemab. Aducanemab has received accelerated approval while Lecanemab has received full approval. Several clinical...
59 KB (4,170 words) - 07:03, 20 October 2024
ransomware attack, causing a shutdown of some of its logistical systems. Lecanemab, branded as "Leqembi" was approved by the U.S. Food and Drug Administration...
12 KB (887 words) - 23:00, 12 November 2024
beta with immunotherapy medications such as donanemab, aducanumab, and lecanemab. Aducanumab was approved by the US Food and Drug Administration (FDA)...
186 KB (19,741 words) - 07:07, 26 December 2024
National Institute for Health and Care Excellence (NICE) confirms that Lecanemab, the first drug developed that slows the early stages of Alzheimer's disease...
489 KB (55,089 words) - 18:20, 3 January 2025
folium N06DX01 Memantine N06DX02 Ginkgo folium N06DX03 Aducanumab N06DX04 Lecanemab N06DX05 Donanemab N06DX30 Combinations "ATC (Anatomical Therapeutic Chemical...
4 KB (443 words) - 04:20, 23 December 2024
Year Approved (US) Year Approved (EU) Additional Information LEQEMBI™ [(lecanemab-irmb)] Indicated for patients with mild cognitive impairment or mild dementia...
48 KB (3,837 words) - 18:51, 12 September 2024
European Medicines Agency recommended the marketing authorisation of lecanemab (anti-beta-amyloid antibody; trade name: Leqembi® from Eisai and Biogen)...
60 KB (6,703 words) - 21:02, 17 December 2024
clinical trials included aducanumab, bapineuzumab, crenezumab, gantenerumab, lecanemab, and solanezumab. Imaging compounds, notably Pittsburgh compound B, (6-OH-BTA-1...
44 KB (4,832 words) - 17:41, 17 November 2024
implementation of the particular Alzheimer's disease therapeutic solution lecanemab may increase annual U.S. Medicare spending by $2.0 to $5.1 billion (11...
489 KB (44,581 words) - 14:24, 1 January 2025
ebolavirus glycoprotein Ebola virus Lebrikizumab mab humanized IL-13 asthma Lecanemab Leqembi mab humanized β-amyloid Y Alzheimer's disease Lemalesomab mab...
138 KB (4,154 words) - 05:18, 17 December 2024
National Institute for Health and Care Excellence (NICE) confirms that Lecanemab, the first drug developed that slows the early stages of Alzheimer's disease...
286 KB (30,521 words) - 20:33, 4 January 2025
estimates made by Alzheimer's Research UK suggested that clinical trials for lecanemab and donanemab would only find 575,000 people living in the UK eligible...
7 KB (549 words) - 21:30, 17 July 2024
making ongoing research and promising developments in treatments like lecanemab incredibly important. The strides being made in understanding the physiological...
116 KB (14,716 words) - 22:29, 14 December 2024
was shown in a large-scale trial of the monoclonal antibody treatment lecanemab. Professor Hardy described the outcome as both "modest" and "historic...
19 KB (1,890 words) - 03:41, 7 November 2024
reported by pharmaceutical companies Eisai and Biogen, using a drug called lecanemab, which is designed to remove beta-amyloid proteins from the brain. A study...
541 KB (49,053 words) - 21:28, 29 December 2024
Dyck is the lead author on the New England Journal of Medicine report on lecanemab, the first treatment to significantly slow the course of Alzheimer's disease...
7 KB (816 words) - 13:49, 10 December 2024